These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 33128625)

  • 21. Simulated Y-site compatibility of atosiban acetate with selected intravenous drugs.
    Jiménez-Lozano I; Larrosa-García M; Boix-Montañés A; Bautista SC; Poy MJC
    Eur J Obstet Gynecol Reprod Biol; 2022 Aug; 275():106-109. PubMed ID: 35779331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.
    Dasta JF; Hale KN; Stauffer GL; Tschampel MM
    Am J Hosp Pharm; 1988 Nov; 45(11):2361-6. PubMed ID: 3228093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-sectional study of potential incompatibility of intravenous medications in a neonatal intensive care unit in Indonesia.
    Mahendra AD; Hanifah S; Sari CP
    Farm Hosp; 2023; 47(1):16-19. PubMed ID: 36707307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings.
    De Silva DTN; Strunk T; Petrovski M; Page-Sharp M; Moore BR; Batty KT
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility of drugs administered as Y-site infusion in intensive care units: A systematic review.
    Castells Lao G; Rodríguez Reyes M; Roura Turet J; Prat Dot M; Soy Muner D; López Cabezas C
    Med Intensiva (Engl Ed); 2020 Mar; 44(2):80-87. PubMed ID: 30262380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Physical compatibility of sodium bicarbonate with other drugs often administered in the intensive care unit].
    Ribas Nicolau B; Pérez Juan E; Amorós Cerdá SM; Arévalo Rubert MJ; Maqueda Palau M
    Enferm Intensiva; 2011; 22(2):78-82. PubMed ID: 21256788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-sectional study of potential incompatibility of intravenous medications in a Neonatal Intensive Care Unit in Indonesia.
    Mahendra AD; Hanifah S; Sari CP
    Farm Hosp; 2023; 47(1):T16-T19. PubMed ID: 36707310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
    Holyk AA; Lindner AH; Lindner SE; Shippert BW
    Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
    Trissel LA; Trusley C; Ben M; Kupiec TC
    Am J Health Syst Pharm; 2007 Jun; 64(11):1209-13. PubMed ID: 17519464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
    Fox LM; Wilder AG; Foushee JA
    Am J Health Syst Pharm; 2013 Mar; 70(6):520-4. PubMed ID: 23456406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
    Avery LM; Chen IH; Reyes S; Nicolau DP; Kuti JL
    Clin Ther; 2019 Oct; 41(10):2162-2170. PubMed ID: 31506218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications.
    Salamat-Miller N; Turner MA; Bandekar A; Dixit N; Jochim E; Mangum B; McPherson C; Tenjarla S; Singh S; Hwang YS; Barton N
    World J Pediatr; 2023 Jan; 19(1):58-67. PubMed ID: 36344872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical compatibility of medications with concentrated neonatal and pediatric parenteral nutrition: A simulated Y-site drug compatibility study.
    Ross EL; Petty K; Salinas A; Her C; Carpenter JF
    JPEN J Parenter Enteral Nutr; 2023 Mar; 47(3):372-381. PubMed ID: 36582024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication Safety in Intravenous Therapy: A Compatibility Study of Clonidine with Drugs Frequently Used in Intensive Care.
    Koller AK; Krebs S; Dörje F
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33374362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
    Trissel LA; Gilbert DL; Martinez JF; Baker MB; Walter WV; Mirtallo JM
    JPEN J Parenter Enteral Nutr; 1999; 23(2):67-74. PubMed ID: 10081995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019.
    Kondo M; Nagano M; Yoshida M; Yoshida N; Tagui N; Yoshida M; Sugaya K; Takase H
    J Nippon Med Sch; 2021 Dec; 88(6):533-539. PubMed ID: 33692301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.